Neil Ettinger

Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension

Ronald J. Raymond, Alan L. Hinderliter, Park W. Willis et al. · Journal of the American College of Cardiology · 2002 · 819 citations

Hypertension, Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension +7

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel et al. · The Lancet Respiratory Medicine · 2019 · 275 citations

Fibrosis, Antifibrotic Therapy, Inflammatory Lung Disease +10

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 216 citations · Full text

Asthma, Pulmonary Care, Phase 2B +6

Cytomegalovirus Infection and Pneumonitis: Impact after Isolated Lung Transplantation

Neil Ettinger, Thomas C. Bailey, Elbert P. Trulock et al. · American Review of Respiratory Disease · 1993 · 199 citations